

Clinical Trial Protocol

Iranian Registry of Clinical Trials

01 Aug 2026

Clinical trial of the effect of probiotic supplementation compared with the placebo on metabolic profiles in patients with diabetic hemodialysis

Protocol summary

Study aim

Objective: The aim of this study is to determine the effects of probiotic supplementation on metabolic profiles in patients with diabetic hemodialysis.

Design

Study design: randomized double-blind placebo-controlled trial. Randomization will be done by the use of computer-generated random numbers. Patients will be assigned into two groups to receive supplement (n=30) or placebo (n=30).

Settings and conduct

Among diabetic hemodialysis patients referred to Akhavan Clinic affiliated to Kashan University of Medical Sciences, Kashan, Iran, 60 patients will be selected according to inclusion and exclusion criteria. Participants, investigators or the assessors of the outcomes are unaware of the study groups. Supplements and placebos are similar in shape and size.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients with diabetic hemodialysis aged 18 to 80 years. Exclusion criteria: Pregnant women, intestinal diseases, taking probiotic supplements and other forms of probiotics including probiotic yogurt, kefir and other fermented foods, taking prebiotic, antioxidant and/or anti-inflammatory supplements such as vitamin E, vitamin C and omega-3 fatty acids, taking antibiotics, immunosuppressive medications within 3 months prior to the enrollment in the study.

Intervention groups

Intervention group: Probiotic supplements containing three strains of *Lactobacillus acidophilus* (2×10^9 CFU/g), *Lactobacillus casei* (2×10^9 CFU/g) and *Bifidobacterium bifidum* (2×10^9 CFU/g), daily, for 12 weeks orally. Control group: Placebo, daily, for 12 weeks orally.

Main outcome variables

Outcomes: Glycemic control (primary outcomes), and lipid profiles, biomarkers of inflammation and oxidative stress (secondary outcomes) will be quantified at study baseline and end-of-trial.

General information

Reason for update

Due to an error, the request for an update in our website was conducted after paper published. However, the revisions were accordance with either the original approved proposal or with coordination with Vice Chancellor of Research at the University.

Acronym

IRCT registration information

IRCT registration number: **IRCT201603185623N69**

Registration date: **2016-03-23, 1395/01/04**

Registration timing: **retrospective**

Last update: **2019-10-28, 1398/08/06**

Update count: **1**

Registration date

2016-03-23, 1395/01/04

Registrant information

Name

Zatollah Asemi

Name of organization / entity

Kashan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 36 1534 3570

Email address

asemi_z@kaums.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research, Kashan University of Medical Sciences

Expected recruitment start date

2016-02-29, 1394/12/10

Expected recruitment end date

2016-03-10, 1394/12/20

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Clinical trial of the effect of probiotic supplementation compared with the placebo on metabolic profiles in patients with diabetic hemodialysis

Public title

Effect of supplementation in treatment of patients with diabetic hemodialysis

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Inclusion criteria: Patients with diabetic hemodialysis aged 18 to 80 years.

Exclusion criteria:

Pregnant women Intestinal diseases Taking probiotic supplements and other forms of probiotics including probiotic yogurt, kefir and other fermented foods Taking prebiotic, antioxidant and/or anti-inflammatory supplements such as vitamin E, vitamin C and omega-3 fatty acids Taking antibiotics, immunosuppressive medications within 3 months prior to the enrollment in the study

Age

From **18 years** old to **80 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Investigator
- Outcome assessor

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

At study baseline and after stratification for pre-intervention BMI and age, subjects will be randomly divided into two groups to take supplementation (n=30) or placebo (n=30). Randomization will be done by the use of computer-generated random numbers.

Blinding (investigator's opinion)

Double blinded

Blinding description

Participants, investigators or the assessors of the outcomes are unaware of the study groups.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Kashan University of Medical Sciences

Street address

Ghotbe Ravandi Boulevard, Kashan

City

Kashan

Province

Isfahan

Postal code

8115187159

Approval date

2016-03-09, 1394/12/19

Ethics committee reference number

IR.Kaums.REC.1394.166

Health conditions studied**1****Description of health condition studied**

همودیالیز

ICD-10 code

N18

ICD-10 code description

Chronic kidney disease

Primary outcomes**1****Description**

Insulin

Timepoint

At the beginning of the study and after 12 weeks of intervention

Method of measurement

Elisa kit

2**Description**

Insulin resistance

Timepoint

At the beginning of the study and after 12 weeks of intervention

Method of measurement

Calculation using HOMA formula

Secondary outcomes

1

Description

Triglycerides

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Enzymatic kit

2

Description

Total cholesterol

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Enzymatic kit

3

Description

HDL

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Enzymatic kit

4

Description

Total antioxidant

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Spectrophotometry

5

Description

Glutathione

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Spectrophotometry

6

Description

Malondialdehyde

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Spectrophotometry

7

Description

Nitric oxide

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Spectrophotometry

8

Description

Hs-CRP

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Elisa kit

9

Description

Creatinine

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Enzymatic kit

10

Description

BUN

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Enzymatic kit

11

Description

Albumin

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Enzymatic kit

12

Description

TIBC

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Enzymatic kit

13

Description

LDL

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Enzymatic kit

14

Description

VLDL

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Enzymatic kit

15

Description

Sodium

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Flame photometry

16

Description

Potassium

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Flame photometry

17

Description

Hemoglobin A1c

Timepoint

At the beginning of the study and 12 weeks after the intervention

Method of measurement

Glycomat kit

Intervention groups

1

Description

Intervention group: Probiotic supplements containing three strains of *Lactobacillus acidophilus* (2×10^9 CFU/g), *Lactobacillus casei* (2×10^9 CFU/g) and *Bifidobacterium bifidum* (2×10^9 CFU/g), daily, for 12 weeks orally.

Category

Treatment - Drugs

2

Description

Control group: Placebo, daily, for 12 weeks orally.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Akhavan Clinic

Full name of responsible person

Zatollah Asemi

Street address

Shahid Rajaee Avenue, Kashan

City

Kashan

Province

Isfahan

Postal code

8115187159

Phone

+98 31 5546 3378

Email

asemi_r@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research, Kashan University of Medical Sciences

Full name of responsible person

Gholamali Hamidi

Street address

Ghotbe Ravandi Boulevard, Kashan

City

Kashan

Province

Isfahan

Postal code

8115187159

Phone

+98 31 5554 0022

Email

research@kaums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice chancellor for research, Kashan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Person responsible for general inquiries

Contact

Name of organization / entity

Kashan University of Medical Sciences

Full name of responsible person

Zatollah Asemi

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Ghotbe Ravandi Boulevard, Kashan

City

Kashan

Province

Isfahan

Postal code

8115187159

Phone

+98 31 5546 3378

Email

asemi_r@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Kashan University of Medical Sciences

Full name of responsible person

Zatollah Asemi

Position

PhD of Nutrition

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Ghotbe Ravandi Boulevard, Kashan

City

Kashan

Province

Isfahan

Postal code

8115187159

Phone

+98 31 5546 3378

Fax
Email

Person responsible for updating data

Contact

Name of organization / entity

Kashan University of Medical Sciences

Full name of responsible person

Zatollah Asemi

Position

PhD of Nutrition

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Ghotbe Ravandi Boulevard, Kashan

City

Kashan

Province

Isfahan

Postal code

8115187159

Phone

+98 31 5546 3378

Fax
Email

asemi_r@yahoo.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available